NEW YORK, March 30 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. (GBI) - announced today that Dr.(med) Kaspar Baenziger has joined GBI’s Corporate Advisory Board.
Dr. Baenziger is a medical doctor trained at the University of Basel in Basel, Switzerland and has a Doctorate in Medicinal Biochemistry. He has held biotechnology investment positions with the international investment banks Lombard, Odier & Cie in Zurich and Deutsche Morgan Grenfell in New York. He has significant marketing and strategic development experience from his tenure at international conglomerate giant Nestle corporation in Switzerland, France and Germany. Recently, he was the Managing Director of the Swiss National Competence Centre of Research in Nanoscience overseeing 240 researchers. Currently, Dr. Baenziger is the founder and CEO of Nexatio Pharmaceuticals in Basel, Switzerland, a private biotechnology company focused on targeted cancer therapies that has demonstrated positive clinical results in compassionate-use trials with its therapy for malignant glioma.
“His international science, business, and investment banking experience will be invaluable to Genesis Bioventures as we increase our commercial and scientific development,” said Douglas C. Lane, President of Experigen Management Company. “Through his extensive international network he has already opened new investment interest in Genesis Bioventures and new scientific development opportunities for our breast cancer diagnostic business, Biomedical Diagnostics, and our prion diagnostic investment, Prion Developmental Laboratories. I have had the pleasure to work with Kaspar on several projects in the US and Europe over the past ten years. I know his outstanding entrepreneurial and creative capabilities and I am delighted he has agreed to participate in our exciting corporate development.”
“Dr. Baenziger’s extensive experience encompasses medical, scientific, and business aspects of different industries and we are very fortunate to have someone with his knowledge and background advising GBI as we move our technologies forward into the marketplace,” said Greg McCartney, President of GBI.
About Experigen
Experigen is a management company retained by Genesis Bioventures, Inc. to develop and advance GBI’s investment portfolio, financing and operations. Mr. Lane is leading Genesis Bioventures’ corporate development and restructuring.
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases.
Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com, www.gnsbio.com Experigen: (310) 443-4100, info@experigen.com, www.experigen.com
Genesis Bioventures Inc.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com,www.gnsbio.com; Experigen: (310) 443-4100, info@experigen.com,www.experigen.com
